Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ832MR)

This product GTTS-WQ832MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ832MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13060MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ747MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ11968MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ3560MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ454MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ8110MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ9101MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ8399MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW